

I hereby certify that this correspondence is being deposited as first-class mail with sufficient postage and is addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 21th day of October 2004 at Facsimile No.

(Signature of person transmitting)

A. David Joran (Reg. No. 37,858)

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Sean Ekins :
APPLICATION NO.: 09/804,176 : Examiner: Brusca, John S.
FILING DATE: March 12, 2001 : Group Art Unit: 1631
TITLE: PHARMACOPHORE MODELS FOR THE :
IDENTIFICATION OF THE CYP2D6 INHIBITORY :
POTENCY OF SELECTIVE SEROTONIN REUPTAKE :
INHIBITORS :

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE TO JULY 21, 2004 COMMUNICATION

This response is submitted in response to the Office Action mailed July 21, 2004, and in further response to the Office Action mailed May 26, 2004, in connection with the above-identified application. A response is due October 21, 2004, with a two-month extension of time, petition for which is submitted herewith. Accordingly, this response is being timely filed.

Please make the following amendment in the subject application:

In the Drawing:

Please replace Figure 1 with substitute Figure 1, submitted herewith.


In response to the Examiner's requirement to elect a single disclosed species, applicant elected the species of Example 2 in the prior Communication. In further response, applicant hereby elects (d,l)-2-methoxy-4,5-methylenedioxyamphetamine as the one species of training compound for examination purposes, and applicant also elects "a partial least squares technique" as the one species of the optimum fit algorithm for examination purposes.

In response to the Drawing Requirement, applicant submits corrected Figure 1, to replace the Figure 1 originally submitted.

If a telephone interview is deemed to be helpful to expedite the prosecution of the subject application, the Examiner is invited to contact applicants' undersigned attorney at the telephone number provided.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Date: October 21, 2004



A. David Joran
Attorney for Applicant(s)
Reg. No. 37,858

Pfizer Inc
Patent Department
150 East 42nd Street – 5th Floor
New York, NY 10017-5755
(212) 733-3381